Review
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
LaTonya J Hickson, Larissa G P Langhi Prata, Shane A Bobart, Tamara K Evans, Nino Giorgadze, Shahrukh K Hashmi + 27 more
ReviewEBioMedicine2019
Research Facts
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
LaTonya J Hickson, Larissa G P Langhi Prata, Shane A Bobart, Tamara K Evans, Nino Giorgadze, Shahrukh K Hashmi + 27 more
Review · Moderate · 2019
Findings

In a small 9-person study, a 3-day treatment combining Dasatinib and Quercetin reduced senescent cells (aging cells that trigger inflammation) in skin and fat tissue within 11 days. The treatment also lowered inflammatory markers in the blood, including IL-6 and MMPs, which are linked to skin aging and degradation.

Design
Review
Evidence
Moderate
Journal
EBioMedicine
Methodology

Researchers gave 9 older adults with diabetic kidney disease oral doses of Dasatinib (100mg) and Quercetin (1000mg) for 3 days, then measured senescent cells in skin and fat biopsies 11 days later.

Funded By

Funded by NIH and multiple foundations